Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN)’s share price traded down 29.3% during mid-day trading on Wednesday . The stock traded as low as $1.14 and last traded at $1.18. 2,694,748 shares changed hands during trading, an increase of 885% from the average session volume of 273,630 shares. The stock had previously closed at $1.67.

Several equities research analysts have recently commented on RNN shares. B. Riley started coverage on Rexahn Pharmaceuticals in a research note on Tuesday, July 31st. They set a “buy” rating and a $7.50 price target on the stock. HC Wainwright set a $20.00 price target on Rexahn Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 25th. Ifs Securities raised Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, October 4th. Finally, Zacks Investment Research raised Rexahn Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.92.

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last announced its quarterly earnings results on Monday, August 6th. The company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03.

A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Northern Trust Corp boosted its stake in Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) by 61.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 77,213 shares of the company’s stock after buying an additional 29,354 shares during the quarter. Northern Trust Corp owned approximately 0.24% of Rexahn Pharmaceuticals worth $117,000 as of its most recent filing with the SEC.

About Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

Read More: Price to Earnings Ratio (PE)

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with's FREE daily email newsletter.